Luk Vandenberghe calls it a “sad irony.”
After decades of ups and downs, gene therapy, which offers a long-lasting genetic fix for a disease, has arrived. A product from Spark Therapeutics called Luxturna, for a rare, inherited type of vision loss, recently became the first-ever approved gene therapy in the U.S., adding to two others in Europe. More products are likely on the way.
And yet Vandenberghe (pictured), the co-director of the Grousbeck Gene Therapy center at Massachusetts Eye and Ear, and his colleagues saw one investor or company after another pass on what they feel could very well be the… Read more »
UNDERWRITERS AND PARTNERS